Form SC14D9C - Written communication relating to third party tender offer:
SEC Accession No. 0001104659-23-103930
Filing Date
2023-09-26
Accepted
2023-09-26 17:06:57
Documents
4

Document Format Files

Seq Description Document Type Size
1 SC14D9C tm2326902d2_sc14d9c.htm SC14D9C 19440
2 EXHIBIT 99.1 tm2326902d2_ex99-1.htm EX-99.1 13453
3 EXHIBIT 99.2 tm2326902d2_ex99-2.htm EX-99.2 13368
4 EXHIBIT 99.3 tm2326902d2_ex99-3.htm EX-99.3 40029
  Complete submission text file 0001104659-23-103930.txt   88019
Mailing Address 305 MADISON AVENUE MORRISTOWN NJ 07960
Business Address 305 MADISON AVENUE MORRISTOWN NJ 07960 646-747-1000
INTERCEPT PHARMACEUTICALS, INC. (Filed by) CIK: 0001270073 (see all company filings)

EIN.: 223868459 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC14D9C
SIC: 2834 Pharmaceutical Preparations

Mailing Address 305 MADISON AVENUE MORRISTOWN NJ 07960
Business Address 305 MADISON AVENUE MORRISTOWN NJ 07960 646-747-1000
INTERCEPT PHARMACEUTICALS, INC. (Subject) CIK: 0001270073 (see all company filings)

EIN.: 223868459 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC14D9C | Act: 34 | File No.: 005-87033 | Film No.: 231281162
SIC: 2834 Pharmaceutical Preparations